Notizie AIOM – anno XVII
FDA Approves Cabozantinib for Advanced HCC
January 14, 2019 - The FDA has approved cabozantinib as a treatment for patients with hepatocellular carcinoma (HCC) who previously received sorafenib, according to the company developing the therapy, Exelixis. The approval was based on findings from the phase III CELESTIAL ...Leggi tutto
FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma
January 15, 2019 - The FDA has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least 1 prior therapy, according to BeiGene, ...Leggi tutto
FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices
January 17, 2019 - The FDA has issued a letter to healthcare providers that they should monitor patients with a type of peripheral arterial disease (PAD) who have been treated with vascular balloons that were coated with paclitaxel or stents that release paclitaxel in the ...Leggi tutto
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer. This was an open label, 1:1 randomized study of cabozantinib ...Leggi tutto